FDA Approves Unknown Drug — ONESOURCE SPECIALTY
ONESOURCE SPECIALTY received FDA approval for its ANDA, marking a strategic entry or expansion into the generic market that is anticipated to generate near-term revenue growth.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day